Results · Oct-Dec 2025 · filed 6 Feb 2026
3B BlackBio Dx Q3 FY26 results
Sales grew 98% to ₹50.3 crore from ₹25.4 crore in Oct-Dec 2024.
Operating profit grew 44% to ₹21.7 crore, an operating margin of 43.1% (down 16.2 points from a year ago).
Net profit grew 66% to ₹22.4 crore from ₹13.5 crore in Oct-Dec 2024.
Against Jul-Sep 2025: sales +49%, net profit +49%.
Get 3B BlackBio Dx's next results & call in your inbox, the day they're filed.
Free. One short email on the days it files or its shares make a big move, nothing on other days. Unsubscribe in one click.
Oct-Dec 2025 vs a year ago
| ₹ crore | Oct-Dec 2025 | Oct-Dec 2024 | Change |
|---|---|---|---|
| Sales | 50.3 | 25.4 | +98% |
| Operating profit (EBITDA) | 21.7 | 15.1 | +44% |
| Operating margin | 43.1% | 59.4% | −16.2 pts |
| Net profit | 22.4 | 13.5 | +66% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 8 quarters
Filings that week
- 7 Feb 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 6 Feb 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 6 Feb 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 6 Feb 2026Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2025
- 6 Feb 2026Board Meeting Outcome for Outcome Of Board Meeting
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.